ICAR- Central Marine Fisheries Research Institute (CMFRI) has entered into an MoU with Emineotech, a health products focused company, last week to commercialize a seaweed based liver health product. The managing director of Emineotech, Evanjalist Pathrose, and Dr. A Gopalakrishnan, Director of CMFRI, executed the license agreement.
The ninth nutraceutical developed by the CMFRI is a one-of-a-kind blend of natural bioactive ingredients extracted from selected seaweeds. It is made using an environmentally friendly green technology to improve liver health.
In addition to boosting immunity, CMFRI has already made nutraceuticals to combat lifestyle diseases like type-2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism, and osteoporosis.
A patent-protected nutraceutical developed by the ICAR-Central Marine Fisheries Research Institute (CMFRI) from seaweeds to treat non-alcoholic fatty liver disease (NAFLD) is referred to as Cadalmin LivCure extract.
In a press release, CMFRI director Dr. A Gopalakrishnan stated, “We have been receiving an overwhelming response from the public ever since the CMFRI developed the Cadalmin LivCure extract, which shows increasing demand for natural remedies against lifestyle diseases.”
He went on to say, “Commercialization of the product will be greatly beneficial to a large number of people suffering from non-alcoholic fatty liver disease because it helps improve liver health, reduce the disposition of fatty substances, and maintain other liver/lipid parameters within the clinically acceptable limits.” According to the findings of in-depth pre-clinical trials, the nutritional supplement does not cause any adverse effects.
He went on to say, “CMFRI launched efforts to the large-scale farming of seaweeds across the coastal states of the country, realizing the high pharmaceutical and medicinal potential of seaweeds.”
The product’s development research was led by Dr. Kajal Chakraborty, the principal scientist at the CMFRI’s marine biotechnology, fish nutrition, and health division.
According to Pathrose, the product will be available for purchase online on Amazon, Flipkart, and other leading e-commerce platforms within four months. It will also be sold in physical market networks across the country. He went on to say that the company would also launch programs to raise community awareness of the dangers of undiagnosed fatty liver disease and the advantages of natural treatments like changing one’s lifestyle.